Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina; Instituto de Patobiología Veterinaria, UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.
Estación Experimental Agropecuaria Balcarce, Instituto Nacional de Tecnología Agropecuaria, RN 226 Km 73.3, Balcarce, Buenos Aires, Argentina.
Int Immunopharmacol. 2020 Apr;81:106269. doi: 10.1016/j.intimp.2020.106269. Epub 2020 Feb 6.
IgY-technology (the production and extraction of specific IgY antibodies from egg yolk) is an innovative method to produce antibodies for therapy and prophylaxis. Advantages of IgY over other antibodies comprise its cost-effective extraction, the minimization of animal harm and distress, and its reduced reactivity with mammalian factors. Many research groups have demonstrated that IgY is active against several pathogens or conditions, a fact that may support the design of novel, safe and effective health products. This review provides a comprehensive analysis of IgY-based biologicals for human medicine, including patent applications and clinical trials during the period 2010-2018, and addresses how IgY-technology can lead to innovation in the production of biologicals for the treatment and prophylaxis of a wide range of infectious and non-communicable diseases.
IgY 技术(从蛋黄中提取特定 IgY 抗体的生产和提取)是一种用于治疗和预防的抗体生产的创新方法。IgY 相对于其他抗体的优势包括其具有成本效益的提取、最小化动物伤害和痛苦以及降低与哺乳动物因素的反应性。许多研究小组已经证明,IgY 对几种病原体或病症具有活性,这一事实可能支持设计新型、安全和有效的保健产品。本综述对 2010-2018 年期间的人用 IgY 生物制品的专利申请和临床试验进行了全面分析,并探讨了 IgY 技术如何引领用于治疗和预防广泛的传染病和非传染性疾病的生物制品的创新。